These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 24692179

  • 41. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.
    Hijazi MM, Thompson EW, Tang C, Coopman P, Torri JA, Yang D, Mueller SC, Lupu R.
    Int J Oncol; 2000 Oct; 17(4):629-41. PubMed ID: 10995872
    [Abstract] [Full Text] [Related]

  • 42. The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition.
    Thakur V, Lu J, Roscilli G, Aurisicchio L, Cappelletti M, Pavoni E, White WL, Bedogni B.
    Oncotarget; 2017 Mar 14; 8(11):17887-17896. PubMed ID: 28060735
    [Abstract] [Full Text] [Related]

  • 43. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
    Sato Y, Yashiro M, Takakura N.
    Cancer Sci; 2013 Dec 14; 104(12):1618-25. PubMed ID: 24112719
    [Abstract] [Full Text] [Related]

  • 44. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD.
    Clin Exp Metastasis; 2008 Dec 14; 25(8):843-54. PubMed ID: 18696232
    [Abstract] [Full Text] [Related]

  • 45. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
    Tan M, Grijalva R, Yu D.
    Cancer Res; 1999 Apr 01; 59(7):1620-5. PubMed ID: 10197638
    [Abstract] [Full Text] [Related]

  • 46. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells.
    Fiddes RJ, Janes PW, Sivertsen SP, Sutherland RL, Musgrove EA, Daly RJ.
    Oncogene; 1998 May 28; 16(21):2803-13. PubMed ID: 9652748
    [Abstract] [Full Text] [Related]

  • 47. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J, Lee J, Kim C, Choi J, Kim A.
    Tumour Biol; 2016 May 28; 37(5):5811-9. PubMed ID: 26581908
    [Abstract] [Full Text] [Related]

  • 48. Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1.
    Zhang Y, Akinmade D, Hamburger AW.
    Cancer Lett; 2008 Jul 08; 265(2):298-306. PubMed ID: 18355957
    [Abstract] [Full Text] [Related]

  • 49. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
    Godinho MF, Wulfkuhle JD, Look MP, Sieuwerts AM, Sleijfer S, Foekens JA, Petricoin EF, Dorssers LC, van Agthoven T.
    Br J Cancer; 2012 Sep 04; 107(6):947-55. PubMed ID: 22892392
    [Abstract] [Full Text] [Related]

  • 50. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
    Yarar D, Lahdenranta J, Kubasek W, Nielsen UB, MacBeath G.
    Mol Cancer Ther; 2015 Sep 04; 14(9):2072-80. PubMed ID: 26116360
    [Abstract] [Full Text] [Related]

  • 51. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N, Pust S, Sandvig K.
    Biochim Biophys Acta; 2014 Sep 04; 1843(9):1987-96. PubMed ID: 24747692
    [Abstract] [Full Text] [Related]

  • 52. Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus.
    Miralem T, Avraham HK.
    Mol Cell Biol; 2003 Jan 04; 23(2):579-93. PubMed ID: 12509456
    [Abstract] [Full Text] [Related]

  • 53. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.
    Chen JY, Chen YJ, Yen CJ, Chen WS, Huang WC.
    Oncotarget; 2016 Jan 05; 7(1):473-89. PubMed ID: 26595522
    [Abstract] [Full Text] [Related]

  • 54. Signaling molecules implicated in heregulin induction of growth arrest and apoptosis.
    Guerra-Vladusic FK, Vladusic EA, Tsai MS, Lupu R.
    Oncol Rep; 2001 Jan 05; 8(6):1203-14. PubMed ID: 11605034
    [Abstract] [Full Text] [Related]

  • 55. The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells.
    Lu Y, Zhou H, Chen W, Zhang Y, Hamburger AW.
    Breast Cancer Res Treat; 2011 Feb 05; 126(1):27-36. PubMed ID: 20379846
    [Abstract] [Full Text] [Related]

  • 56. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
    Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J, Pry K, Westlund R, Stein SH, Spector NL.
    Cancer Res; 2007 Feb 01; 67(3):1170-5. PubMed ID: 17283152
    [Abstract] [Full Text] [Related]

  • 57. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
    Schaefer G, Fitzpatrick VD, Sliwkowski MX.
    Oncogene; 1997 Sep 18; 15(12):1385-94. PubMed ID: 9333014
    [Abstract] [Full Text] [Related]

  • 58. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH, Jo JY, Han JY.
    Mol Cancer Ther; 2018 Sep 18; 17(9):2024-2033. PubMed ID: 29959202
    [Abstract] [Full Text] [Related]

  • 59. Expression and differential signaling of heregulins in pancreatic cancer cells.
    Kolb A, Kleeff J, Arnold N, Giese NA, Giese T, Korc M, Friess H.
    Int J Cancer; 2007 Feb 01; 120(3):514-23. PubMed ID: 17096356
    [Abstract] [Full Text] [Related]

  • 60. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
    Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX.
    Cancer Cell; 2002 Aug 01; 2(2):127-37. PubMed ID: 12204533
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.